CUTANA Cloud
EpiCypher's CUT&RUN/Tag epigenomics analysis platform powered by DNAnexus
Company profile
Company profile
DNAnexus operates the Precision Health Data Cloud, a comprehensive platform trusted by hundreds of biomedical organizations worldwide to accelerate scientific discovery and improve patient care. The company provides an enterprise-grade cloud infrastructure that enables pharmaceutical companies, academic medical centers, clinical diagnostics labs, biobanks, and population health programs to manage, analyze, and collaborate on multiomics and multimodal precision health data. The DNAnexus Platform breaks down data silos by creating a single source of truth for genomic, clinical, and other biomedical data types. It offers rapid workflow development with support for multiple bioinformatics languages including Nextflow and WDL, pre-built tools and apps, and seamless integration with existing technology ecosystems including sequencers and R&D applications. The platform features AI and machine learning capabilities for predictive analytics, cohort analysis tools, integrated JupyterLab notebooks, and data visualization applications. DNAnexus serves the entire precision medicine lifecycle from research through clinical diagnostics, with specialized solutions including Innovation Hubs, NGS Data Analysis, Translational Informatics, Population Genomics, and Trusted Regulatory Spaces for regulatory submissions. The company maintains partnerships with major cloud providers and technology partners, and powers large-scale initiatives including the UK Biobank Research Analysis Platform. With regulatory-grade security and compliance certifications, DNAnexus enables organizations to scale on-demand while maintaining data governance and supporting global regulatory collaboration.
Company description DNAnexus official website
Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Cloud Saas deployment with recorded integration context.
Recorded integration context: EHR systems, Epic, Oracle, R&D lifecycle applications, Sequencers.
Company milestones
DNAnexus and Oracle partnership to link genomic data to EHRs; ARPA-H adaptive cancer treatment program; World's largest single-cell dataset available on platform; EpiCypher CUTANA Cloud launch; Accelerated Cure Project for MS Data Challenge Pilot; Longitude Prize Discovery Team selections; Boehringer Ingelheim Prix Galien USA finalist
Partnerships
02 · Flagship portfolio
Selected source-backed Company products and the available commercial context.
EpiCypher's CUT&RUN/Tag epigenomics analysis platform powered by DNAnexus
The world's most trusted platform for precision health where multiomic data and AI converge
Solution for accelerating biomedical innovation and scientific discovery
Next-generation sequencing data analysis solution with pre-built bioinformatics tools
Large-scale population genomics analysis and biobank data management solution
FDA-powered collaborative platform for sponsor-reviewer interaction and multi-omics analysis
Bridge research and clinical applications with integrated multiomics and clinical data
Cloud-based regulatory collaboration framework for life sciences compliance and submission
Dedicated research analysis platform for UK Biobank data access and analysis
03 · Research intelligence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Advanced science (Weinheim, Baden-Wurttemberg, Germany) · May 29, 2026
microRNA-422a promotes HIV replication and innate immune evasion by targeting MECP2.Molecular therapy. Nucleic acids · Mar 12, 2026
The ADAPT learning cancer treatment system: ARPA-H's initiative to revolutionize cancer therapy.Cancer cell · Mar 9, 2026
Selecting medical research data platforms for translational biomedical research: a five-tier overview and requirement-weighted assessment framework.Frontiers in digital health · Jan 1, 2026
The challenge of chromatin model comparison and validation: A project from the first international 4D Nucleome Hackathon.PLoS computational biology · Aug 1, 2025
Predicting the impact of rare variants on RNA splicing in CAGI6.Human genetics · Mar 1, 2025
Clinical validation
NCT02910037 · Sponsor · COMPLETED
Regulatory
No linked records are currently available.
04 · Company-reported outcomes
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
Return on investment for DNAnexus customers
Time spent deploying new bioinformatics pipelines
Immediate time-to-value vs DIY environments that take over a year to build
Cloud transformation through Trusted Regulatory Spaces for regulatory intelligence and policy
2025 Prix Galien USA finalist
Launching ACP Data Challenge Pilot for multiple sclerosis research
Pioneering game-changing adaptive cancer treatment research
Launching CUTANA Cloud for CUT&RUN/Tag epigenomics analysis
Powering precisionFDA Collaborative Omics Environment for enhanced sponsor-reviewer interaction and multi-omics support
Scaling genomic testing operations to impact patient outcomes
Enabling precision medicine research with world's largest biobank dataset
World's largest single-cell dataset available
05 · Leadership
Leadership profiles and professional links from the current Company record.
06 · Company updates
Recent articles published on DNAnexus's official website.
07 · HAIC coverage
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Curated official destinations from the active Company record.
09 · Market pathway
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Companies using AI to analyze genomic, proteomic, metabolomic, or multi-omics data to provide personalized treatment recommendations, identify genetic risks, or develop targeted therapies. Includes genomic sequencing platforms with AI analysis, preventive medicine based on genetic risk assessment, and longevity care based on molecular and genetic data.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market10 · Pro research
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.